Long Focus Capital Management LLC Boosts Stock Position in Aura Biosciences, Inc. (NASDAQ:AURA)

Long Focus Capital Management LLC grew its holdings in shares of Aura Biosciences, Inc. (NASDAQ:AURA) by 113.4% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,057,188 shares of the company’s stock after acquiring an additional 561,766 shares during the quarter. Long Focus Capital Management LLC’s holdings in Aura Biosciences were worth $7,992,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in AURA. The Manufacturers Life Insurance Company grew its position in Aura Biosciences by 14.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 64,452 shares of the company’s stock worth $487,000 after acquiring an additional 8,194 shares during the last quarter. Renaissance Technologies LLC grew its holdings in shares of Aura Biosciences by 26.3% in the second quarter. Renaissance Technologies LLC now owns 72,100 shares of the company’s stock worth $545,000 after purchasing an additional 15,000 shares during the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Aura Biosciences by 20.0% in the second quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company’s stock worth $1,892,000 after buying an additional 41,711 shares during the period. American Century Companies Inc. bought a new stake in Aura Biosciences during the 2nd quarter valued at $119,000. Finally, Levin Capital Strategies L.P. boosted its position in Aura Biosciences by 194.5% during the 2nd quarter. Levin Capital Strategies L.P. now owns 327,466 shares of the company’s stock valued at $2,476,000 after buying an additional 216,266 shares during the period. 96.75% of the stock is currently owned by institutional investors.

Aura Biosciences Stock Up 4.2 %

Shares of AURA stock opened at $9.01 on Friday. The business’s fifty day moving average is $8.70 and its 200 day moving average is $7.91. The stock has a market cap of $446.38 million, a price-to-earnings ratio of -4.84 and a beta of 0.35. Aura Biosciences, Inc. has a twelve month low of $5.99 and a twelve month high of $12.35.

Aura Biosciences (NASDAQ:AURA) last released its earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.04. Equities research analysts expect that Aura Biosciences, Inc. will post -1.7 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the stock. Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a report on Monday, September 9th. Evercore ISI raised Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 16th. HC Wainwright reiterated a “buy” rating and issued a $21.00 price objective on shares of Aura Biosciences in a research report on Friday, September 13th. Finally, JMP Securities raised their price target on Aura Biosciences from $19.00 to $23.00 and gave the stock a “market outperform” rating in a research note on Friday, September 13th. Three analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $21.67.

Aura Biosciences Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.